Snapshot from Jul 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Ionis Pharma trial fails, stock drops
Business clinical trial failure

Ionis Pharma trial fails, stock drops

Analysis based on 11 articles · First reported Jul 10, 2026 · Last updated Jul 14, 2026

Sentiment
-40
Attention
3
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Ionis Pharmaceuticals shares fell over 20% on the trial failure, erasing significant market value. The investigation may lead to shareholder lawsuits, further pressuring the stock and potentially affecting investor confidence in Ionis's pipeline.

biotechnology pharmaceuticals
Event Summary

On July 9, 2026, Ionis Pharmaceuticals announced that its Phase-3 CARDIO-TTRansform trial, partnered with AstraZeneca, failed to meet its primary endpoint of reducing combined cardiovascular death and recurrent events in patients with transthyretin-mediated amyloid cardiomyopathy. The stock opened down more than 20% on the news. Levi & Korsinsky commenced an investigation into potential securities law violations, focusing on whether prior statements by CEO Brett Monia regarding the trial's progress were materially false or misleading. The investigation covers statements made on November 6, 2024 and June 10, 2026.

Key Actions
100 Ionis Pharmaceuticals disclosed trial failure
80 Ionis Pharmaceuticals made statements
70 Levi & Korsinsky commenced investigation Ionis Pharmaceuticals
50 Ionis Pharmaceuticals partnered with AstraZeneca
Entities Involved
stock
Ionis Pharmaceuticals
Ionis Pharmaceuticals is the central entity; its Phase-3 trial failure caused a >20% stock drop and triggered a securities investigation.
Importance 100.0 Sentiment -80.0
per
Brett Monia
Brett Monia, CEO of Ionis, made optimistic statements about the trial that are now under investigation; his credibility may be damaged.
Importance 50.0 Sentiment -60.0
priv
Levi & Korsinsky
Levi & Korsinsky is the law firm investigating potential securities law violations on behalf of Ionis shareholders; they stand to gain from any settlement.
Importance 40.0 Sentiment 0.0
stock
AstraZeneca
AstraZeneca was the partner in the CARDIO-TTRansform trial; the failure may affect their collaboration but has limited direct impact on AstraZeneca's stock.
Importance 30.0 Sentiment -10.0
per
Joseph E. Levi
Joseph E. Levi is a partner at Levi & Korsinsky leading the investigation; his role is procedural.
Importance 10.0 Sentiment 0.0
exch
Nasdaq
Nasdaq is the exchange where Ionis is listed; the event has no material impact on the exchange itself.
Importance 5.0 Sentiment 0.0
Relationships
Levi & Korsinsky related ↔ Joseph E. Levi
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.